Initiating antiepileptic drug (AED) treatment after a first seizure remains a controversial issue because of our lack of understanding of the underlying mechanisms of brain injury and the subsequent processes that lead to injured brain becoming epileptic. Current treatment for established epilepsy requires long-term treatment with drugs that have obvious limitations. The currently available drugs have antiseizure activity but lack antiepileptogenic properties. Despite extensive mechanistic experimental research being performed during the last decades, the process of epileptogenesis remains poorly understood. Consequently, no antiepileptogenic drugs have been developed yet. Moreover, current AEDs, including new generation drugs have considerable side effects, both acute and chronic. Second-generation AEDs may be better tolerated but are no more effective than traditional AEDs. Because of our lack of understanding of the underlying mechanism of action of AEDs attempts to rationally prescribe and combine AEDs in different types of seizures and epilepsy syndromes have largely failed. 1 Clearly, we need to shift gears and change the paradigms for future drug development in epilepsy.
These fundamental issues were intensively discussed during the 1st Ghent International Epilepsy Workshop, an international key opinion leader meeting held in Gent, Belgium on May 21-23, 2010. As a result of this meeting, the current issue of Seizure, the European Journal of Epilepsy publishes 3 invited reviews by international experts and groups in the field of antiepileptic drug development and therapy.
Dr. Wolfgang Lö scher provides a comprehensive overview of the current status of animal models for seizures and epilepy. These models have played a fundamental role in advancing our understanding of basic mechanisms underlying ictogenesis and epileptogenesis and have been instrumental in the discovery and preclinical development of novel AEDs. However, there is growing concern that the efficacy of drug treatment of epilepsy has not substantially improved with the introduction of new AEDs. This may be due to the fact that only the same simple screening models, i.e., the maximal electroshock seizure (MES) and sc. pentylenetetrazole (PTZ) seizure tests, have been used in AED discovery. These old models may identify only drugs that share characteristics with existing drugs, and are unlikely to have an effect on refractory epilepsies. Experience with several novel AEDs, including levetiracetam, has shown that the MES and PTZ models do not identify all potential AEDs and may fail to discover compounds that have great potential efficacy but work through mechanisms not tested by these models. Lö scher 2 argues that preclinical strategies of AED discovery and development need a conceptual shift that is moving away from using models that identify therapies for the symptomatic treatment of epilepsy to those that may be useful for identifying therapies that are more effective in the refractory population and that may ultimately lead to an effective cure in susceptible individuals by interfering with the processes underlying epilepsy. Furthermore in this issue of Seizure, Dr. Martin Brodie & Dr. Graeme Sills critically review the limitations of current AEDs in terms of pharmacological properties and interactions and they specifically examine the concept of ''rational polytherapy''. They review the available animal and human data exploring the issue showing that the experimental and clinical evidence in favour of rational polytherapy is scarse. The only sound evidence available to support this concept is the positive synergism demonstrated by the combination of lamotrigine and valproate. Consequently, robust information to guide clinicians on when and how to combine currently available AEDs is necessarily empirical. Despite this lack of evidence-based data, Brodie and Sills 3 argue that the availability of an increasing number of AEDs with different although incompletely understood mechanisms of action have provided a modest improvement in the outcome of epilepsy, in particular in patients with refractory epilepsy. Because of the intrinsic limitations of systemic delivery and our limited understanding of the mechanisms of action of current AEDs, new and innovative approaches are warranted. Local delivery of AEDs directly into the brain may be an attractive treatment option for epilepsy. Higher therapeutic drug levels may be reached at the targeted brain region and systemic side effects avoided. In this issue of Seizure, Dr. Annelies Van Dycke et al. 4 provide an overview of the currently investigated experimental and clinical local delivery strategies in the brain ranging from delivery via pump mechanisms to more advanced techniques with cell and gene therapy. They particularly focus on local brain delivery strategies for epilepsy with special attention to adenosine. Adenosine is a good candidate for local delivery techniques for epilepsy because of its proven anticonvulsive effect and it cannot be given systemically because of systemic side effects. Local delivery using polymers and pumps are controllable sources, but have the disadvantage of the need for refilling or replacement. Transplantation of adenosine releasing stem/neural progenitor cells can resolve this problem since long-term integration and secretion of adenosine is possible. Despite the fact that this last strategy is currently hampered by a limited control on cell integration and adenosine release after transplantation further studies with evaluation of long-term effects of cell-based therapies are warranted. The future of cell-based therapies in epilepsy seems promising.
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